Navigation Links
IntelliCyt Launches Novel Assay System to Accelerate Cell Line Development
Date:3/16/2017

IntelliCyt, a Sartorius Company, and a leading provider of integrated platforms that accelerate drug discovery, antibody screening and immuno-oncology research today announced the launch of the Cy-Clone Plus assay system for ranking and selection of clones for cell line development using the iQue Screener PLUS platform. A key factor in reducing the production costs of biopharmaceuticals is the development of cell lines producing a high yield of product. The Cy-Clone PLUS selection strategy is designed to identify clones that are highly productive and have optimal growth characteristics.

IntelliCyt’s iQue Screener PLUS platform is an integrated instrument, software, and reagent system that offers rapid, multiplexed analysis of cell and bead-based samples in 96, and 384 well plates. The iQue Screener’s proprietary sampling technology uniquely enables efficient assessment of cells in suspension, and miniaturizes the assay format, which conserves precious samples for further analysis. Profiling phenotypic and functional endpoints of cells, while simultaneously analyzing secreted proteins through the use of bead-based assays, generates rich information from the fewest numbers of cells. Plates are processed quickly, and software-assisted automation, analysis, and experiment-level visualization tools instantly rank and reveal the best clones for further analysis.

“Cy-Clone PLUS will greatly streamline the clone ranking and selection workflow for cell line development,” said R. Terry Dunlay, President and CEO of IntelliCyt. “By measuring the critical productivity attributes of each clone, finding the healthiest producers is fast, cost effective, and easy.”

About IntelliCyt

IntelliCyt Corporation,a Sartorius Company, manufactures and sells instrumentation, software and reagents that facilitate the study of cells and their components to gain a better understanding of normal and disease processes. This information speeds the discovery and development of new drugs and provides new insight for the diagnosis of diseases. IntelliCyt’s products are used worldwide throughout the pharmaceutical and biotechnology industries and in nonprofit research labs. For more information, please visit http://www.intellicyt.com.

About Sartorius
The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.3 billion euros in 2016. Around 7,000 people work for the Group, which has its own manufacturing and sales sites in around 110 countries.

Read the full story at http://www.prweb.com/releases/2017/03/prweb14129356.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. IntelliCyt Launches iQue® Screener PLUS to Accelerate Suspension-cell Screening and Combinatorial Profiling for Immunological Applications
2. Genedata and IntelliCyt Forge Alliance to Transform Cell-based Screening in Drug Discovery
3. SpectraGenetics Joins IntelliCyt’s Technology Alliance Partner Program
4. IntelliCyt Corporation Completes $7.4 Million in New Financing
5. IntelliCyt and FIMM Announce a Collaboration to Advance Personalized Medicine in Cancer Treatment
6. AstraZeneca Enters into an Agreement with IntelliCyt for the Development of High Throughput Biology Applications
7. Massachusetts General Hospital Enters Into a Technology Alliance Partnership with IntelliCyt for the Development of CRISPR Functional Screening Applications
8. IntelliCyt Announces a New Addition to the iQue® Screener PLUS Platform During CYTO 2016
9. Notable Labs Enters into a Collaboration Agreement with IntelliCyt to Develop a Phenotypic Personalized Medicine Platform for Cancer Patients
10. Darrow Wealth Management Launches New Website
11. Guidepoint Global Launches Two Major Enhancements to its Client Research Portal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... PA (PRWEB) , ... March 28, 2017 , ... ... spoke at a Marketing Roundtable on March 22 in Philadelphia. The event was ... , The Marketing Roundtable featured breakout groups and interaction with ...
(Date:3/28/2017)... WASHINGTON , March 28, 2017  (AACR17, ... single-cell sequencing during the American Association for Cancer Research ... Center in Washington, D.C. , April ... gene expression of thousands of cells at the individual ... Experts on-hand at AACR to discuss expanded ...
(Date:3/28/2017)... , March 28, 2017 Dr. ... life sciences corporation Anpac Bio-Medical Science Company ... new, international record, processing and reporting over 40,000 ... Differentiation Analysis" (CDA) liquid biopsy tests. ... Prize Laureate Summit publications, Anpac Bio,s CDA medical ...
(Date:3/28/2017)... Focus is on the ... to the scientifically intensive operations of companies in ... and industrial. In today,s pre-market research, Stock-Callers.com dedicates attention ... PTLA), OvaScience Inc. (NASDAQ: OVAS), Ocera Therapeutics Inc. ... OCUL ). Learn more about these stocks ...
Breaking Biology Technology:
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
(Date:3/7/2017)... , March 7, 2017   HireVue , ... top global companies identify the best talent, faster, today ... Chief Sales Officer (CSO) and Diana Kucer ... round out a seasoned executive team poised to drive continued ... building on a year of record bookings in 2017. ...
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
Breaking Biology News(10 mins):